

Factsheet

Our Mission

We use best-in-class enzyme engineering and production technologies to deliver superior biotech solutions enabling innovative industrial applications for partners in food and pharma.

Our Vision

We want to develop c-LEcta into a recognized, global leader for high-performance enzymes promoting human health.

Metrics

Revenue 2021
20 Mio. Euro

Employees
120+

Clients
400+

Patents
100+

Majority
shareholder
Kerry Group

Management



Dr. Marc Struhalla, CEO

More than 15 years of experience in the commercialisation of biotechnological industrial products



Thomas Pfaadt, CFO

Expertise from management positions in corporate finance and investor relations in the healthcare sector


Products

c-LEcta supplies over 400 customers in more than 40 countries with biotechnologically manufactured quality products.

Applications


Pharma

Gene therapy
Cell therapy
Medical Products
Vaccines
Patented chemical drugs
Generic Drugs



Food

Food & Beverages
Single cell proteins
Dietary Supplements
Phage production
Food Enzymes
Yeast extracts



Other

Feed Enzymes
Biofilm degradation
Cosmetics



Technology


c-LEcta uses its proprietary technology platform ENESYZ to develop customised enzymes and microbial production strains that meet the requirements of a wide range of manufacturing processes in industry. It has been continuously developed since its foundation in 2004. In the last 18 years, we have carried out more than 50 enzyme engineering projects with a success rate of >90%.

Why work with c-LEcta?



We meet the highest quality requirements of our customers in the pharmaceutical and food industries throughout the entire product life cycle.

c-LEcta works in collaborations with industry partners to jointly develop new products and bring them to market.



As one of the leading technology companies for products manufactured by fermentation, c-LEcta also offers its skills to the industry as a production partner.